Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan.
COVID-19
epidemiology
inflammatory bowel disease
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
08
06
2020
revised:
21
06
2020
accepted:
23
06
2020
pubmed:
27
6
2020
medline:
22
1
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
It is unsure whether inflammatory bowel disease (IBD) is a risk factor for novel coronavirus infection (COVID-19). IBD patients were identified from population-based databases in Hong Kong and Taiwan from January 21, 2020, until April 15, 2020. Total 2954 and 2554 IBD patients were identified in Hong Kong and Taiwan, respectively. None had COVID-19. Pooled analysis showed that 65.3%, 39.1%, 4.3%, and 12.8% IBD patients in Hong Kong and 75.8 %, 51.4 %, 26.1%, and 52.3 % in Taiwan were on 5-aminosalicylates, immunomodulators, corticosteroids, and biologics, respectively. There were no reported cases of COVID-19 infection amongst IBD patients in Hong Kong and Taiwan. IBD patients should continue their usual medications during the COVID-19 pandemic.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
It is unsure whether inflammatory bowel disease (IBD) is a risk factor for novel coronavirus infection (COVID-19).
METHODS
METHODS
IBD patients were identified from population-based databases in Hong Kong and Taiwan from January 21, 2020, until April 15, 2020.
RESULTS
RESULTS
Total 2954 and 2554 IBD patients were identified in Hong Kong and Taiwan, respectively. None had COVID-19. Pooled analysis showed that 65.3%, 39.1%, 4.3%, and 12.8% IBD patients in Hong Kong and 75.8 %, 51.4 %, 26.1%, and 52.3 % in Taiwan were on 5-aminosalicylates, immunomodulators, corticosteroids, and biologics, respectively.
CONCLUSION
CONCLUSIONS
There were no reported cases of COVID-19 infection amongst IBD patients in Hong Kong and Taiwan. IBD patients should continue their usual medications during the COVID-19 pandemic.
Identifiants
pubmed: 32589798
doi: 10.1111/jgh.15164
pmc: PMC7361268
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-173Informations de copyright
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):525-527
pubmed: 32311321
Lancet Public Health. 2020 May;5(5):e279-e288
pubmed: 32311320
BMC Musculoskelet Disord. 2012 Aug 27;13:158
pubmed: 22925480
Nature. 2020 May;581(7806):15-16
pubmed: 32341558
Nat Rev Immunol. 2020 May;20(5):271-272
pubmed: 32296135
Gastroenterology. 2020 Aug;159(2):481-491.e3
pubmed: 32425234
Gut. 2020 Jul;69(7):1213-1217
pubmed: 32354990
J Pediatr Gastroenterol Nutr. 2020 Jun;70(6):727-733
pubmed: 32443020
Ann Rheum Dis. 2020 Jul;79(7):859-866
pubmed: 32471903
Gastroenterology. 2020 Jul;159(1):371-372
pubmed: 32247695
Gut. 2020 Jul;69(7):1335-1342
pubmed: 32303609
Gastroenterology. 2020 Aug;159(2):781-783
pubmed: 32330477
J Gastroenterol Hepatol. 2021 Jan;36(1):171-173
pubmed: 32589798